Tim Bartels
Overview
Explore the profile of Tim Bartels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2610
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lam I, Ndayisaba A, Lewis A, Fu Y, Sagredo G, Kuzkina A, et al.
Neuron
. 2025 Feb;
113(4):637.
PMID: 39894019
No abstract available.
2.
Roman-Vendrell C, Wallace J, Watson A, Celikag M, Bartels T, Morgan J
J Physiol
. 2024 Nov;
PMID: 39530449
Synaptic aggregation of α-synuclein often occurs in Parkinson's disease (PD), dementia with Lewy bodies (DLB) and other synucleinopathies and is associated with cognitive deficits and dementia. Thus, it is important...
3.
Bhattacharya S, Xu L, Arrue L, Bartels T, Thompson D
J Chem Inf Model
. 2024 Oct;
64(20):8010-8023.
PMID: 39377660
Controlling the polymorphic assemblies of α-synuclein (αS) oligomers is crucial to reroute toxic protein aggregation implicated in Parkinson's disease (PD). One potential mediator is the interaction of αS tetramers with...
4.
Eubanks E, VanderSleen K, Mody J, Patel N, Sacks B, Farahani M, et al.
bioRxiv
. 2024 Sep;
PMID: 39257816
Alpha-synuclein (αSyn) is an intrinsically disordered protein that accumulates in the brains of patients with Parkinson's disease and forms intraneuronal inclusions called Lewy Bodies. While the mechanism underlying the dysregulation...
5.
Lam I, Ndayisaba A, Lewis A, Fu Y, Sagredo G, Kuzkina A, et al.
Neuron
. 2024 Jul;
112(17):2886-2909.e16.
PMID: 39079530
The heterogeneity of protein-rich inclusions and its significance in neurodegeneration is poorly understood. Standard patient-derived iPSC models develop inclusions neither reproducibly nor in a reasonable time frame. Here, we developed...
6.
De Boni L, Wallis A, Watson A, Ruiz-Riquelme A, Leyland L, Bourinaris T, et al.
EMBO Mol Med
. 2024 Jun;
16(7):1657-1674.
PMID: 38839930
Synucleinopathies such as Parkinson's disease (PD) are defined by the accumulation and aggregation of the α-synuclein protein in neurons, glia and other tissues. We have previously shown that destabilization of...
7.
Dorion M, Yaqubi M, Senkevich K, Kieran N, Macdonald A, Chen C, et al.
Brain
. 2023 Sep;
147(2):427-443.
PMID: 37671615
Mer tyrosine kinase (MerTK) is a receptor tyrosine kinase that mediates non-inflammatory, homeostatic phagocytosis of diverse types of cellular debris. Highly expressed on the surface of microglial cells, MerTK is...
8.
Fazzari M, Di Biase E, Zaccagnini L, Henriques A, Callizot N, Ciampa M, et al.
Biochim Biophys Acta Mol Cell Biol Lipids
. 2023 Jun;
1868(9):159350.
PMID: 37330108
Fibrillary aggregated α-synuclein represents the neurologic hallmark of Parkinson's disease and is considered to play a causative role in the disease. Although the causes leading to α-synuclein aggregation are not...
9.
Ramalingam N, Jin S, Moors T, Fonseca-Ornelas L, Shimanaka K, Lei S, et al.
NPJ Parkinsons Dis
. 2023 Jan;
9(1):4.
PMID: 36646701
In Parkinson's disease and other synucleinopathies, the elevation of α-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined....
10.
De Boni L, Watson A, Zaccagnini L, Wallis A, Zhelcheska K, Kim N, et al.
Acta Neuropathol
. 2022 Feb;
143(4):453-469.
PMID: 35141810
The protein α-synuclein, a key player in Parkinson's disease (PD) and other synucleinopathies, exists in different physiological conformations: cytosolic unfolded aggregation-prone monomers and helical aggregation-resistant multimers. It has been shown...